What “microdosing” a GLP-1 means
It is a nickname for taking less than an approved dose, and no approved product is dosed that way. The smallest step on the WEGOVY injection label is 0.25 mg once a week, and the label puts it there to reduce stomach side effects on the way up.
On this page
What the approved doses actually are
Both semaglutide labels start low and climb, and both say why. The injection begins at 0.25 mg once weekly for four weeks; the tablets begin at 1.5 mg once daily for 30 days. Neither figure is a maintenance dose, and the label is direct about what the climb is for:2,3
Follow the dosage escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6), Adverse Reactions (6.1)].
So the small doses exist, and they are approved. What does not exist in either document is a dose below them, or a word for one. The semaglutide dosage chart has both ladders in full.
What the word departs from
“Microdosing” borrowed its name from a different field, and in this one it covers anything from a fraction of a starting dose to stretching an approved dose across extra weeks. It has no agreed definition, no strength behind it and no product labeled for it. Searching both prescribing information documents this site cites for the word, and for “micro-dose” and “micro dose”, returns nothing in either.
The clinical literature that does use the word is small and recent. A 2026 report in the Journal of the American Association of Nurse Practitioners describes the practice and what pushes people toward it:4
the drivers behind subtherapeutic microdosing (specifically gastrointestinal tolerability and "vanity weight"); the specific side effects and dosing errors encountered with these practices; the safety risks associated with pen manipulation, compounded vials, and medication sharing
Two things in that sentence are worth separating. Stomach tolerability is a real problem with a labeled answer, and it is not the same as wanting a smaller result. How long semaglutide side effects last has what the trials measured about the first, and staying on a low dose of WEGOVY has what the label allows about the second.
What has and has not been measured
The trials behind the labels tested the labeled ladder. In the weight trials people escalated to 2.4 mg over 16 weeks and stayed there, and where the label compares two doses head to head, both are doses on that ladder: 1.7 mg against 2.4 mg in one trial, 2.4 mg against 7.2 mg in two others. No arm sits at a fraction of a starting dose, so there is no result to quote for one.2
That is a gap in the evidence rather than a verdict. What it means in practice is that anybody telling you how much weight a microdose takes off, or how safe one is, is filling in a blank the labels and their trials leave open.
Where the drug at those doses comes from
An approved pen is not sold in fractions, so a microdose usually means either a compounded vial measured by hand or a pen used against its instructions. FDA has published what it has received on the first:
FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products. These dosing errors resulted from patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses of the drug.
The same page sets the regulatory frame around the product itself: compounded drugs are not FDA approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed, and FDA says they should only be used when a patient’s medical need cannot be met by an approved drug. As of 31 May 2026 it had received 990 reports of adverse events associated with compounded semaglutide, with the caveat that federal law does not require many pharmacies to report them at all. What a compounded prescription is covers that distinction, and what a plan does with it.1
The money question nobody answers first
Microdosing is often framed as a way to spend less. On this market it usually is not. 41 of the 92 sellers priced here state that their figure does not change with the dose, so a smaller dose buys the same bill. The Bayan Health review distinguishes its separately marketed microdose program from its standard injection plan and initial commitment. That service comparison is not evidence that a microdose is appropriate or effective.
What semaglutide costs by dose has each seller’s own figure with the wording it is quoted on, and what it costs as the weeks go on multiplies one out over a stretch of treatment.
Questions
Is microdosing safer than a full dose?
The sources reviewed here do not establish that. The trials behind the labels tested the labeled ladder, and the labels put the low doses at the start of it to reduce stomach side effects rather than to be stayed on. What FDA has published about doses outside the label is reports of adverse events, including from dosing errors.
Does a smaller dose cost less?
Usually not, on this market. Most of the sellers priced here that say anything about dose say their price holds at every one, so a smaller dose buys the same monthly figure. The maker’s own tablet pricing works the other way, rising with the dose.
Is my 0.25 mg starting dose a microdose?
No. 0.25 mg once weekly is the approved starting dose on both semaglutide injection labels, and it has four weeks of its own in the schedule. It is the bottom of the ladder rather than something below it.
My prescriber wants to keep me at a lower dose. Is that microdosing?
Not in the sense the word is used online. The WEGOVY label allows 1.7 mg as a maintenance dose alongside 2.4 mg and tells prescribers to consider delaying a step by four weeks when a dose is not tolerated. That is the label being used, not departed from.
Read next
Sources
A reference, not medical advice, and not a substitute for your prescriber or pharmacist. If you think you are having a medical emergency, call your local emergency number.